← Back to headlines
Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery
Morgan Stanley has identified Rocket Pharmaceuticals (RCKT) as a key beneficiary of the anticipated biotech sector recovery in 2026.
19 Feb, 00:44 — 19 Feb, 00:44
ℹOnly 1 source covers this story
